Menu

LivaNova PLC LIVN

Full chart Compare
Set alert

Price alert · LIVN

All alert types
89.99 USD -1.15 (-1.26%)

At closeNov 6, 2026, 4:00 PM EST

89.99 0.00 0.00%

After hours · Nov 6, 4:00 PM ET

88.42 Day range 91.51
49.57 52-week range 94.19
YTD
+46.25%
1 year
+81.54%
Market cap
4.96B
Revenue (ttm)
1.51B
Profit margin
13.01%
EPS (ttm)
3.49
Shares out
55.09M
P/E ratio
25.79
Forward P/E
19.22
YTD return
+46.25%
1-year return
+81.54%
Volume
444.00K
Avg volume
674.92K
Open
90.09
Previous close
91.14
Day's range
88.42 – 91.51
52-week range
49.57 – 94.19
Beta
0.92
Analysts
Buy
Price target
90.55 (+0.6%)
Earnings date
Feb 24, 2027

3M +13.77 (+18.07%)

8090Aug 17Sep 3Sep 23Oct 12Oct 2989.99

Key statistics

Enterprise value
4.81B
PEG ratio
0.93
Price / sales
3.29
Price / book
3.61
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
9.90%
Free cash flow
67.71M
Total cash
563.47M
Total debt
357.07M
Return on equity
15.50%
Short % of float
12.92%
50-day average
79.08
200-day average
73.37

Financials — quick view

All financials
LIVN Revenue — quarterly 393.15M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
LIVN Net income — quarterly 34.29M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
LIVN EPS — quarterly 0.62
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

LIVN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 20261.07———
Nov 4, 2026Sep 30, 20261.061.23+0.17+16.04%
Aug 5, 2026Jun 30, 20261.091.26+0.17+15.60%
May 6, 2026Mar 31, 20260.850.98+0.13+15.29%
Feb 25, 2026Dec 31, 20250.800.86+0.06+7.50%
Nov 5, 2025Sep 30, 20250.9191.11+0.19+20.78%

Upgrades / downgrades

LIVN analyst upgrades and downgrades
DateFirmActionFromTo
Nov 5, 2026BairdmainOutperformOutperform
Nov 4, 2026NeedhammainBuyBuy
Oct 7, 2026Barclaysinit—Overweight
Sep 2, 2026Piper SandlerreitOverweightOverweight
Aug 5, 2026NeedhammainBuyBuy
Jul 15, 2026MizuhomainOutperformOutperform

About LivaNova PLC

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.

Sector
Healthcare
Industry
Medical Devices
Country
United Kingdom
Website
livanova.com

News

Your note

Sign in to keep a note on LIVN — it syncs with the Stock Master app.

Insider holders

LIVN insider holders
InsiderRelationLatest transactionDateShares held
BARRY JAMES CHRISTOPHERDirectorConversion of Exercise of derivative securityJun 14, 20267,918
BOLTON STEPHANIEOfficerConversion of Exercise of derivative securityMar 29, 202622,189
ENXING SENG STACYDirectorConversion of Exercise of derivative securityJun 14, 202615,307
KOZY WILLIAM ADirectorConversion of Exercise of derivative securityJun 14, 202637,566
MAKATSARIA VLADIMIR A.Chief Executive OfficerConversion of Exercise of derivative securityMar 29, 202614,167
O'KANE SHARONDirectorConversion of Exercise of derivative securityJun 12, 202511,304

Institution ownership

LIVN institution ownership
Holder% heldSharesValueReported
Blackrock Inc.13.73%7,565,342680.81MJun 29, 2026
Primecap Management Company7.57%4,168,377375.11MJun 29, 2026
FMR, LLC5.71%3,147,068283.20MJun 29, 2026
Hood River Capital Management LLC4.66%2,565,477230.87MJun 29, 2026
AQR Capital Management, LLC4.28%2,356,191212.03MJun 29, 2026
Invesco Ltd.4.06%2,237,319201.34MJun 29, 2026

Fund ownership

LIVN fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Mid-Cap ETF3.56%1,963,642176.71MSep 29, 2026
VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund3.45%1,902,700171.22MJun 29, 2026
AIM Sector Funds (Invesco Sector Funds)-Invesco Small Cap Value Fund3.05%1,679,556151.14MJul 30, 2026
American Century ETF Trust-Avantis U.S. Small Cap Value ETF2.92%1,607,363144.65MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.63%1,450,682130.55MSep 29, 2026
Artisan Partners Funds Inc.-Artisan International Small-Mid Fund2.50%1,374,576123.70MJun 29, 2026